Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche receives approval to expand Avastin breast cancer label

Roche receives approval to expand Avastin breast cancer label

1st July 2011

Roche has been granted approval from the European Commission to expand the breast cancer treatment specification of its drug Avastin.

The regulatory body has ratified the drug for use in combination with Xeloda among patients with metastatic breast cancer, in addition to its existing approval in combination with paclitaxel chemotherapy.

Approval was granted for this new treatment method based on positive data from the phase III Ribbon 1 trial, showing the improvements this therapy option can deliver in terms of progression-free survival.

This new approval offers an additional treatment choice for women who are unable to benefit from alternative therapy methods.

Dr Hal Barron, chief medical officer and head of global product development at Roche, said: "The decision received from the EU Commission supports our belief that Avastin provides a clinically meaningful benefit in combination with Xeloda."

Earlier this month, the company published data from the phase III study Oceans, which demonstrated the efficacy of Avastin among ovarian cancer patients.ADNFCR-8000103-ID-800608407-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.